Zenas BioPharma, Inc. (ZBIO) Deep Dive Video

Name: Zenas BioPharma, Inc. (ZBIO) Deep Dive Video | Flash
Uploaded: 2025-10-16T12:00:23.5
Description: A de-risked Phase 3 autoimmune antibody with orphan exclusivity meets a high-stakes first launch—while a CNS-penetrant BTK program offers blockbuster MS optionality under liver-safety scrutiny.

Summary

A de-risked Phase 3 autoimmune antibody with orphan exclusivity meets a high-stakes first launch—while a CNS-penetrant BTK program offers blockbuster MS optionality under liver-safety scrutiny.

View ZBIO stock page · Read the ZBIO research report

Loading the video player…